07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Leukemia inhibitory factor receptor α (LIFR; CD118)-knockdown mouse model of osteolytic bone metastases of breast cancer

Disease models TECHNOLOGY: Transgenics and knockouts An LIFR-knockdown mouse model of metastatic breast cancer could be useful for screening therapies to treat osteolytic bone metastases of the cancer. In a xenograft mouse model of metastatic...
07:00 , Aug 25, 2011 |  BC Innovations  |  Cover Story

Cardiotrophin workout

A team at the University of Navarra has shown that obesity and metabolic syndrome can be treated with cardiotrophin-1, a cytokine that regulates energy utilization and appetite. 1 The findings open up a new indication...
08:00 , Jan 21, 2010 |  BC Innovations  |  Targets & Mechanisms

Oncostatin's LIFR sentence

A key challenge in developing osteoporosis therapies that actually promote bone growth-most marketed drugs stop bone loss-is uncoupling the tightly related processes of bone formation and resorption. Now, a group of Australian researchers has found...
08:00 , Jan 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis Oncostatin M (OSM); leukemia inhibitory factor receptor-a (LIFR; CD118) A study in mice suggests increasing OSM signaling through LIFR could help treat osteoporosis....
07:00 , Jun 3, 2002 |  BioCentury  |  Tools & Techniques

Attacking apoptosis in MS

Drugs that are marketed to treat multiple sclerosis modulate the immune system, but they do not inhibit the mechanisms that drive the neuropathology of the disease. Now two reports in Nature Medicine show that cytokines...
08:00 , Mar 19, 2001 |  BC Week In Review  |  Clinical News

Leukemia inhibitory factor regulatory update

Invirion received notice of allowance for a U.S. patent covering the use of the gp130- LIFR gene to produce LIF, a naturally occurring protein that Invirion said inhibits HIV-1 replication. Invirion Corp., Chicago, Ill.  ...